PharmaCyte Biotech, Inc.
PMCB
$0.94
$0.044.34%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -131.19% | -104.18% | 9,083.97% | 1,877.84% | 1,866.55% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 106.91% | 87.33% | -1,156.80% | -2,145.37% | -4,593.89% |
| Change in Net Operating Assets | 948.12% | 233.87% | 353.95% | 323.97% | 84.85% |
| Cash from Operations | -133.41% | -60.37% | -38.43% | -7.78% | 21.58% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 75.00% | 100.00% | -40.00% | -40.00% | -- |
| Cash from Investing | 75.00% | 100.00% | -40.00% | -40.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -100.00% |
| Repurchase of Common Stock | 89.34% | 27.49% | 90.98% | 88.68% | 89.28% |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | -100.00% |
| Repurchase of Preferred Stock | 89.35% | 51.53% | -28.42% | -300.71% | -2,487.37% |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 105.41% | 45.29% | -133.74% | -723.48% | -3,557.09% |
| Foreign Exchange rate Adjustments | -190.00% | 42.86% | 25.00% | 75.47% | 111.11% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 89.67% | 53.70% | -96.01% | -292.19% | -1,386.55% |